Recce Pharmaceuticals Ltd (ASX:RCE) has lodged a Final Director's Interest Notice for Alistair McKeough, disclosing his securities holdings at the time he ceased to be a director on 6 November 2026, with his last notice previously dated 16 May 2025.

Key Points

  • Alistair McKeough ceased to be a director of Recce Pharmaceuticals Ltd on 6 November 2026.
  • Finn Frist Pty Ltd, as trustee for the AZM Superannuation Fund, held 30,287 fully paid ordinary shares in which McKeough had a relevant interest.
  • Amabel Pty Limited, as trustee for the McKeough Family Trust, held 1,125,000 unlisted options exercisable at $1.56, expiring 15 November 2027.
  • Amabel Pty Limited also held 1,000,000 unlisted options exercisable at $0.80, expiring 14 November 2029.

Director Cessation and Filing Details

The Final Director's Interest Notice was submitted by Recce Pharmaceuticals Ltd (ABN 73 124 849 065) under ASX Listing Rule 3.19A.3 and as agent for Alistair McKeough pursuant to section 205G of the Corporations Act. The filing records that McKeough ceased to hold the position of director on 6 November 2026. His most recent prior interest notice was dated 16 May 2025. The filing discloses no securities held by McKeough as a registered holder directly in his own name, with Part 1 of the notice recording nil securities in that category.

Securities Held Through Associated Entities

McKeough's relevant interests at the time of ceasing as director were held through two associated entities. Finn Frist Pty Ltd, acting as trustee for the AZM Superannuation Fund, held 30,287 fully paid ordinary shares in Recce Pharmaceuticals. McKeough is disclosed as a director and shareholder of the trustee and a beneficiary of the trust. Amabel Pty Limited, as trustee for the McKeough Family Trust, held the unlisted options disclosed in the notice. McKeough is a director of that trustee and a beneficiary of that trust.

Unlisted Options Held by Amabel Pty Limited

Amabel Pty Limited held two tranches of unlisted options in Recce Pharmaceuticals at the date McKeough ceased to be a director. The first tranche comprises 1,125,000 unlisted options, each exercisable at $1.56, with an expiry date of 15 November 2027. The second tranche comprises 1,000,000 unlisted options, each exercisable at $0.80, with an expiry date of 14 November 2029. The filing records no interests in contracts for McKeough, with Part 3 of the notice disclosing not applicable across all relevant fields.